Personalis ( (PSNL) ) has released its Q2 earnings. Here is a breakdown of the information Personalis presented to its investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Personalis, Inc., based in Fremont, California, is a leader in advanced genomics for precision oncology, specializing in personalized cancer testing to guide patient care and enhance drug development strategies.
In its second quarter of 2025 financial report, Personalis highlighted significant clinical momentum with a 59% sequential growth in test volume, driven by increased adoption of its NeXT Personal platform. The company also expanded its commercial partnership with Tempus AI, Inc. to include colorectal cancer, and presented pivotal clinical data at the 2025 ASCO Annual Meeting.
Key financial metrics revealed a revenue of $17.2 million, a 24% decrease from the previous year, primarily due to a decline in revenue from Natera and other pharma services. However, population sequencing revenue saw a 158% increase. The company reported a net loss of $20.1 million, with a gross margin decrease to 27.6% from 35.6% the previous year.
Despite the current financial challenges, Personalis remains optimistic about its strategic objectives for 2025, including securing Medicare coverage for two indications. The company’s management is focused on driving clinical use of its NeXT Personal platform and expanding its commercial capabilities to support future growth.